Axsome Therapeutics, Inc.
Company Stats
- Market Cap
- $9.7B
- as of Sep 30, 2026
- Enterprise Value
- $9.5B
- Shares Outstanding
- 52.4M
- Free Float
- 64.5%
Income Statement
- Revenue
- $638.5M
- Operating Income
- -$166.8M
- Net Income
- -$183.2M
- EBITDA
- -$166.3M
- Revenue Growth, 3Y
- 133.7%
- FCF Margin, 3Y Avg
- -34.0%
- FCF Margin, Worst Year
- -53.8%
Cash Flow
- Free Cash Flow
- -$93.9M
- FCF Yield
- -1.0%
- Owner FCF Yield
- -1.9%
Balance Sheet
- Cash & Equivalents
- $322.9M
- Total Debt
- $120.0M
- Net Cash
- $202.9M
Returns & Capital
- SBC, 3Y Avg
- $80.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $638.5M | -$93.9M | -14.7% |
| FY2024 | $385.7M | -$128.7M | -33.4% |
| FY2023 | $270.6M | -$145.7M | -53.8% |
| FY2022 | $50.0M | -$117.2M | -234.3% |
| FY2021 | — | -$108.5M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 31, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back